Levels of mannose-binding lectin (MBL) associates with sepsis-related in-hospital mortality in women

Sofie Jacobson 1*, Peter Larsson 1, Anna-Maja Åberg 1, Göran Johansson 1, Ola Winsö 1 and Stefan Söderberg 2

Abstract

Background: Mannose-binding lectin (MBL) mediates the innate immune response either through direct opsonisation of microorganisms or through activation of the complement system. There are conflicting data whether MBL deficiency leads to increased susceptibility to infections or not. The aim of this study was to determine if low levels of mannose-binding lectin (MBL) predict sepsis development, sepsis severity and outcome from severe sepsis or septic shock.

Method: Patients aged 18 years or more with documented sepsis within 24 h after admission to the intensive care unit were included if they had participated in a health survey and donated blood samples prior to the sepsis event. A subset of these patients had stored plasma also from the acute phase. Two matched referents free of known sepsis were selected for each case. Plasma levels MBL were determined in stored samples from health surveys (baseline) and from ICU admission (acute phase). The association between MBL and sepsis, sepsis severity and in-hospital mortality were determined with 1300 ng/mL as cut-off for low levels.

Results: We identified 148 patients (61.5% women) with a first-time sepsis event 6.5 years (median with IQR 7.7) after participation in a health survey, of which 122 also had samples from the acute septic phase. Both high MBL levels in the acute phase (odds ratio [95% confidence interval] 2.84 [1.20–6.26]), and an increase in MBL levels from baseline to the acute phase (3.76 [1.21–11.72]) were associated with increased risk for in-hospital death in women, but not in men (0.47 [0.11–2.06]). Baseline MBL levels did not predict future sepsis, sepsis severity or in-hospital mortality.

Conclusions: An increase from baseline to the acute phase as well as high levels in the acute phase associated with an unfavourable outcome in women.

Keywords: Sepsis, Mannose-binding lectin, Sex, Case-referent study

Background

Severe sepsis is a life-threatening syndrome where little is known about factors determining susceptibility for developing the syndrome and severity of the syndrome once developed. Potentially, biomarkers could be used for identifying those at risk for severe sepsis needing aggressive treatment, which is subject for intensive studies [1–4]. With advances in recombinant techniques, targeted substitution therapies are forthcoming and one of the challenges will be to define which patients will benefit from such therapies [5–7].

Mannose-binding lectin (MBL) is a serine protease belonging to the collectin family and is believed to be an important factor in the innate immune system, the first line host defence. With its pattern-recognizing ability, MBL binds to the surface of a wide range of microorganisms,
although not all, thus functioning either as a direct opsonin, or through activation of the complement system, thereby enhancing phagocytosis of microorganisms by macrophages and neutrophils [8].

There are several known mutations in the structural MBL2-gene and its promoter regions located at the long arm of chromosome 10, resulting in a large number of haplotypes. This genetic polymorphism is associated with different levels of MBL expression and activity [9–13].

There are several reports indicating that genotypes associated with low levels of MBL may predispose to certain forms of infection or impaired immune response, particularly in new-borns, but also in adults [14–17]. Other reports indicate that low levels of MBL may augment the humoral immune system [18–23]. However, there are considerable overlaps in MBL concentrations between different genotypes, and inter-individual variability among individuals with identical genotypes is significant [10–13, 24, 25]. Different definitions and cut-off values have been used to define MBL deficiency [17, 26–29] and genotypes associated with low MBL production are common, as high as 25–30% in certain populations [25, 29].

Several studies on the association of MBL genetic polymorphism and/or MBL plasma levels with severe infections, sepsis and septic shock, have shown an increased risk of sepsis development and unfavourable outcome in MBL deficient patients [27, 28, 30, 31]. However, there are conflicting results [26, 32–34].

In this nested case-referent study we hypothesized that low MBL levels associate with increased risk of future sepsis, and its severity, and in contrast, that high levels associates with decreased risk of sepsis and sepsis related mortality. Furthermore, that the MBL-associated risk is similar in men and women.

**Material and methods**

Design and methods have been previously reported [35]. Shortly, cases were identified retrospectively within health survey cohorts and biomarkers were analyzed in blood samples collected at the health surveys (baseline) and when available, in blood samples collected at admission to the intensive care unit (acute phase).

A total of 797 patients were admitted with a diagnosis of sepsis at the Intensive Care Unit, Umeå University Hospital, Sweden, between 1 March 1988 and 31 October 2008.

The diagnosis of sepsis and the severity of sepsis were confirmed retrospectively by reviewing hospital records, including results from biochemical, microbiological, and radiological examinations.

Of the 797 patients, 148 had prior to the septic event participated in one of four population-based health studies in Northern Sweden: the Västerbotten Intervention Program (VIP), the Northern Sweden MONItoring Of trends and Determinants in CArdivascular Disease (MONICA) survey, the Mammary Screening Program (MSP), and the Northern Sweden Maternity Cohort (NSMC). The contribution of cases from each survey was 80 (VIP), 4 (MONICA), 42 (MSP), and 22 (NSMC). The Northern Sweden Health and Disease Study (NSHD S) which includes the three former studies, and the Northern Sweden Maternity Cohort (NSMC) are described in detail in our previous report [35].

Patients aged 18 years or older were included if they had a diagnosis of sepsis within 24 h after admittance to the ICU. Only the first event was included for patients with multiple admissions due to sepsis. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) were used [36]. Acute Physiology, Age, Chronic Health Evaluation II score (APACHE II) was calculated for assessment of severity of illness at admission [37]. Sequential Organ Failure Assessment Score (SOFA) was calculated as a marker for organ dysfunction and disease severity [38].

Data on length of stay, mortality, referral patterns, and reasons for admission, co-morbidities, and sources of infection, primary infection sites and causative microorganisms were collected. Microbiological cultures acquired within 48 h before or after admission to the ICU were considered relevant. Pre-existing diseases were defined according to Knaus et al. [37].

For each case, two referents without any episode of sepsis and being alive at the date of the case admission to ICU were chosen and matched for age (± 2 years), gender, health survey, and time of blood sampling (± 30 days). Matching on smoking (y/n) was incomplete due to missing information, mainly in the MSP.

In addition, 122 out of 148 patients had also retrievable samples collected at ICU admission (the acute phase). Thus, 122 patients had samples from both the health survey examination (baseline) and from admission to the ICU (the acute phase).

The study protocol was approved by the Regional Ethical Review Board in Umeå and by the Swedish National Computer Data Inspection Board, and complies with the Declaration of Helsinki. All participants gave written informed consent for future use of data and blood samples.

**Chemical analyses**

MBL in plasma was analysed in duplicates using a commercially available ELISA (MBL Oligomer ELISA Kit 029, BioPorto Diagnostics, Gentofte, Denmark) in accordance with the instructions from the manufacturer. The absorbance was read on a spectrophotometer (Labsystems Multiskan MS, Triad Scientific Inc., USA). The range of the assay was 0 to 4000 ng/mL. The
distribution of MBL in healthy Danish blood donors analysed with the same assay was provided by the manufacturer. There was no significant difference in MBL distribution when comparing the Danish cohort with our study cohort (Supplementary Table 5 and 6).

Statistical analyses
Data are presented as numerical values or percentages. Continuous data are presented as median with interquartile range. For comparisons, Fisher’s exact, Mann-Whitney U-tests or Wilcoxon Signed Rank test were used when appropriate. Spearman correlation test was used for correlation. Since cases and referents had the same follow-up time within strata in this nested and matched case-referent study, logistic regression analysis (rather than Cox regression) using the conditional maximum likelihood routine designed for matched analysis was used to estimate odds ratios with 95% confidence intervals (CI), and the influence of MBL on future sepsis was tested in a univariable model. Non-conditional logistic regression (only cases) analysis was used to calculate the risk for in-hospital death. Mannose-binding lectin was tested as a categorical variable with 1300 ng/ml as cut-off for low levels [27]. The accuracy of this cut-off was tested with Receiver Operator Characteristic (ROC) graphs with calculation of the area under the curve (AUC). The change in MBL levels from baseline to the acute phase (the difference in MBL levels between baseline and the acute phase) was also tested as a categorical variable. The cut-off was set at zero, with positive values representing an increase and negative values representing a decrease from baseline to the acute phase. The accuracy of this cut-off was also tested with ROC analysis. A \( p \)-value < 0.05 was considered significant, and all \( p \)-values reported are two-sided. SPSS ver. 24 was used for statistical analysis.

Results
Sixty-one percent of both cases and referents were women (matched), and there was no difference in age between cases and referents (matched) but women were younger than men at baseline survey, 49.8 years and 53.2 years, respectively \( (P = 0.003) \). Cases had marginally higher BMI than referents \( (P = 0.04) \) but the prevalence of diabetes, hypertension, hypercholesterolemia and smoking did not differ (Table 1).

Circulating MBL levels at baseline did not differ between cases and referents \( (P = 0.5) \) (Table 2). However, when comparing men and women in the whole cohort women had slightly lower levels at baseline than men \( (P = 0.04) \), but there was no difference between female cases and their referents \( (P = 0.5) \), or between male cases and their referents \( (P = 0.9) \) (Fig. 1). Further, the distribution of low and high MBL levels (cut-off 1300 ng/mL) did not differ between cases and referents or between men and women (Table 2).

Patient characteristics at ICU admission are shown in Table 3. Women were younger when developing sepsis \( (P = 0.04) \), and the period between the baseline survey and the sepsis event was 7.4 years (IQR 7.8) for men and 5.9 years (IQR 8.1) for women \( (P = 0.04) \). Of the events, 67% were classified as severe sepsis and 33% as the most severe form, the septic shock. Severity of sepsis, APACHE II- and SOFA score, length of stay, ICU- and in-hospital mortality did not differ between men and women. There were no differences in co-morbidities, sources of infection and infecting microorganisms between men and women except for infections with gram negative rods which was slightly more frequent in men \( (P = 0.04) \).

MBL levels at ICU admission (samples available from 122 patients) did not differ between men and women \( (P = 0.7) \). However, MBL levels in the acute phase were significantly lower than baseline levels in both men and

---

Table 1 Subject characteristics at baseline surveys

| Subject characteristic          | Cases       | 95% CI   | Referents  | 95% CI   |
|---------------------------------|-------------|----------|------------|----------|
| Age years                       | 148/296     | 51.1     | 49.0–53.2  | 51.1     | 49.6–52.6 | (matched) |
| Female gender, %                | 91/182      | 61.5     | 53.6–69.4  | 61.5     | 55.9–67.1 | (matched) |
| BMI, kg/m²                      | 116/229     | 27.6     | 26.5–28.7  | 26.4     | 25.8–26.9 | 0.04       |
| Reduced glucose tolerance, %    | 80/151      | 35.0     | 24.3–45.7  | 23.8     | 17.0–30.7 | 0.16       |
| Daily smoker, % #               | 116/237     | 28.4     | 20.1–36.8  | 28.7     | 22.9–34.5 | (matched) |
| Hypertension, %                 | 83/158      | 55.4     | 44.5–66.4  | 43.0     | 35.2–50.8 | 0.08       |
| Systolic BP, mmHg               | 83/158      | 135      | 130–139    | 132      | 129–135   | 0.34       |
| Diastolic BP, mmHg              | 83/158      | 82       | 80–85      | 82       | 80–83     | 0.74       |
| Cholesterol, mmol/L             | 83/155      | 5.7      | 5.4–5.9    | 6.0      | 5.8–6.2   | 0.06       |

Values reported are means or percentages % with 95% CI. Hypertension was defined as systolic BP > 140 mmHg and/or diastolic BP > 90 mmHg and/or antihypertensive treatment. Reduced glucose tolerance included any of IFG, IGT or DM. Referents were matched with cases based on age, sex and (if available) smoking status.

Abbreviations: DM Diabetes mellitus, IFG Impaired fasting glucose, IGT Impaired glucose tolerance, BP Blood pressure.
women ($P = 0.03$ and $P < 0.05$, respectively) (Fig. 2). Co-
morbidities, sources of infection and infecting microorgan-
isms did not differ in those with low MBL levels defined as
levels below 1300 ng/mL compared to patients with MBLle-
vels above 1300 ng/mL (data not shown).

Circulating MBL levels at baseline did not correlate
with age ($r = -0.02$, $P < 0.8$), BMI ($r = -0.02$, $P < 0.9$),
fasting or post-load glucose levels, ($r = 0.05$, $P = 0.6$ and
$r = -0.07$, $P = 0.5$, respectively), or with systolic or dia-
stolic blood pressures ($r = -0.07$, $P = 0.6$ and $r = -0.15$,
$P = 0.2$, respectively). Similarly, MBL levels in the acute
phase did not correlate with age ($r = 0.09$, $P = 0.3$), BMI
($r = -0.02$, $P = 0.9$), APACHE II score ($r = 0.10$, $P = 0.3$),
or SOFA score ($r = 0.08$, $P = 0.4$). Circulating levels of
MBL in the acute phase did not correlate to MBL at
baseline ($r = 0.004$, $P = 1.0$). Correlation analysis stratified
by sex did not add any more information, neither at baseline nor in the acute phase (data not shown).

Low levels at baseline expressed as circulating MBL
below 1300 ng/mL did not predict a future sepsis event
(0.82 [0.55–1.23]), or increased severity; severe sepsis
(0.94 [0.58–1.54]), septic shock (0.64 [0.32–1.27]), or
hospital death (1.29 [0.54–3.08]). Similar point estimates
were seen when stratified for sex. Several other cut-offs
were also tested, but lower levels (than 1300 ng/mL) did
not associate with future sepsis development, sepsis
severity or hospital outcome (Supplementary Table 4).

Women who died had significantly higher levels in the
acute phase than surviving women ($P = 0.005$), and they
had also higher levels than men who died ($P = 0.02$)
(Fig. 3).

Intra-individual MBL levels decreased significantly
from baseline to the acute phase in women who survived
($P = 0.002$). Further, there was a significant difference in
the change of MBL levels in surviving women compared
to non-surviving women ($P = 0.003$). In men, the intra-
individual changes did not differ between survivors or
non-survivors ($P = 0.6$) (Fig. 4).

The association between MBL levels in the acute phase
and in-hospital death was analysed, with 1300 ng/mL as
cut-off. The accuracy of the chosen cut-off (1300 ng/mL)
was tested in a ROC analysis showing a diagnostic
accuracy of 65.6% at 1319 ng/mL, with a sensitivity of
68.1% and specificity of 57.1% for the whole group. AUC
was 0.60 (0.48–0.72, 95%CI), $p = 0.044$. For women, the
ROC analysis showed a diagnostic accuracy of 73.3%
at 1319 ng/mL, with a sensitivity of 72.4% and specific-
ity of 76.5%. AUC was 0.73 (0.59–0.86, 95%CI), $P =
0.0008$. For men, no discrimination point was detected
(Supplementary Figures 7, 8 and 9, respectively).

### Table 2 MBL concentration (ng/mL) at baseline survey for cases and referents

| Cases          | Referents          | Cases          | Referents          |
|----------------|--------------------|----------------|--------------------|
| n              | n                  | MBL (ng/mL)    | MBL (ng/mL)        |
| MBL conc. (ng/mL) | 148 (42.6%) | 140 (47.3%) | 1464 (IQR 3095) | 1401 (IQR 2305) |
| MBL > = 1300 (ng/mL) | 85 (57.4%) | 156 (52.7%) | 2863 (IQR 2170) | 2671 (IQR 2101) |

Data are presented as numbers (%) and median with interquartile range (IQR)

---

**Fig. 1** MBL concentrations (ng/mL) at baseline survey for men and women, cases and referents. Men are displayed to the left in the panel and women to the right. Empty boxes represent referents and filled boxes represent cases. Data are presented as median and interquartile range (IQR).
## Table 3: Patient characteristics at ICU admission

|                                | All patients (n = 148) | Men (n = 57) | Women (n = 91) |
|--------------------------------|------------------------|--------------|----------------|
| Age years                      | 60.7 (IQR 18.3)        | 63.4 (IQR 16.5) | 57.2 (IQR 18.0) |
| Years between survey and sepsis| 6.5 (IQR 7.7)          | 7.4 (IQR 7.8)  | 5.9 (IQR 8.1) *|
| BMI (n = 116, 52/64)           | 26.7 (IQR 6.0)         | 26.0 (IQR 6.2) | 26.9 (IQR 7.0) |
| Disease scores                 |                        |              |                |
| APACHE II Score                | 18.0 (IQR 9)           | 17.0 (IQR 10) | 18.0 (IQR 9)   |
| SOFA score                     | 7.0 (IQR 5)            | 7.0 (IQR 5)   | 7.0 (IQR 6)    |
| Disease severity, n (%)        |                        |              |                |
| Severe sepsis                  | 99 (66.9%)             | 42 (74%)     | 57 (63%)       |
| Septic shock                   | 49 (33.1%)             | 15 (26%)     | 34 (37%)       |
| ICU mortality                  | 27 (18.2%)             | 10 (17.5%)   | 17 (18.7%)     |
| Hospital mortality             | 32 (21.6%)             | 13 (22.8%)   | 19 (20.9%)     |
| Hospital Length of stay        | 17.5 (IQR 24.7)        | 15 (IQR 25.5) | 18 (IQR 27)    |
| Co-morbidities, n (%)          |                        |              |                |
| COPD                           | 4 (2.7%)               | 1 (1.8%)     | 3 (3.3%)       |
| Congestive heart failure       | 5 (3.4%)               | 3 (5.3%)     | 2 (2.2%)       |
| Chronic renal insufficiency    | 4 (2.7%)               | 2 (3.5%)     | 2 (2.2%)       |
| Chronic liver disease          | 0 (0%)                 | 0 (0%)       | 0 (0%)         |
| Diabetes, n (%)                |                        |              |                |
| Insulin treatment              | 11 (7.4%)              | 4 (7.0%)     | 7 (7.7%)       |
| Other treatments               | 8 (5.4%)               | 4 (7.0%)     | 4 (4.4%)       |
| Cancer, n (%)                  |                        |              |                |
| Hematological                  | 9 (6.1%)               | 4 (7.0%)     | 5 (5.5%)       |
| Localized                      | 20 (13.5%)             | 9 (15.8%)    | 11 (12.1%)     |
| Metastatic                     | 11 (7.4%)              | 5 (8.8%)     | 6 (6.6%)       |
| Immunosuppressants, n (%)      |                        |              |                |
| Chronic steroids               | 8 (5.4%)               | 3 (5.3%)     | 5 (5.5%)       |
| Chemotherapy                   | 13 (8.8%)              | 7 (12.3%)    | 6 (6.6%)       |
| Other immunosuppression        | 12 (8.1%)              | 4 (7.0%)     | 8 (8.8%)       |
| Primary infection site, n (%)  |                        |              |                |
| Pneumonia                      | 24 (16.2%)             | 11 (19%)     | 13 (14%)       |
| Abdominopelvic                 | 50 (33.8%)             | 19 (33%)     | 31 (34%)       |
| Urinary tract                  | 20 (13.5%)             | 10 (18%)     | 10 (11%)       |
| Other                          | 52 (35.1%)             | 17 (30%)     | 35 (38%)       |
| Unknown                        | 5 (3.4%)               | 2 (3.5%)     | 3 (3.3%)       |
| Infecting microorganism, n (%) |                        |              |                |
| Gram positive (cocci)          | 62 (14.0%)             | 23 (40.4%)   | 39 (42.9%)     |
| Gram negative (rods)           | 40 (27%)               | 21 (36.8%)   | 19 (20.9%) *   |
| Fungi                          | 11 (7.4%)              | 3 (5.3%)     | 8 (8.8%)       |
| Virus                          | 9 (6.1%)               | 3 (5.3%)     | 6 (6.6%)       |
| Negative cultures              | 33 (22.3%)             | 13 (22.8%)   | 20 (22.0%)     |

Data are presented as numbers (%) or median and interquartile range (IQR)

* p < 0.05 Mann-Whitney and Chi2. Abbreviations: APACHE Acute Physiology, Age and Chronic Health Evaluation, SOFA Sequential Organ Failure Assessment, CI Confidence interval, IQR Interquartile range, COPD Chronic obstructive pulmonary disease, ICU Intensive care unit
High levels associated with in-hospital death (2.84 [1.20–6.76]). In the stratified analysis, the association remained in women (8.53 [2.42–30.07] but not in men (0.59 [0.13–2.61]). The association remained for women even after adjustment for APACHE II score and for SOFA score separately (Fig. 5). Furthermore, an increase from baseline to the acute phase associated with hospital death in women (3.76 [1.27–11.72]) but not in men (0.47 [0.11–2.06]) (Fig. 6). In a ROC analysis a diagnostic accuracy of 73.3% for the risk of in hospital death for women was found at an increase of 516 ng/mL from baseline to the acute phase, with a sensitivity of 75.9% and specificity of 64.7%. AUC was 0.74 (0.61–0.87, 95%CRI), \(p = 0.0001\) but no discriminating point could be seen in men, (Supplementary Figure 10 and 11, respectively).

**Discussion**

We report that low levels of MBL in a pre-sepsis state did not associate with a future sepsis event. Further, in
In the acute phase of sepsis, there were sex-related differences in MBL levels in relation to in-hospital mortality. Women who died in hospital had higher levels than surviving women. This association between MBL levels and outcome was not seen in men. Furthermore, an increase in MBL levels from baseline to the acute phase associated with hospital death in women but not in men. To our knowledge, the association between circulating MBL levels and sepsis outcome in women has not been previously reported. This finding indicates the presence of sex-related differences related to innate immunity. It has been reported that ‘resting’ MBL levels in women may be higher than those of men of similar age, though others have not made such observation [39, 40].

**Fig. 4** MBL (ng/mL). Differences between MBL levels in the acute phase and at baseline for survivors (S) and non-survivors (NS) displayed for men and women separately. Men are displayed to the left in the panel, and women to the right. Empty boxes represent survivors and filled boxes represent non-survivors. For each box a negative value represents a decrease and a positive value represents an increase, (MBL_acute phase - MBL_baseline) > 0 = increase from baseline to the acute phase, (MBL_acute phase - MBL_baseline) < 0 = decrease from baseline to the acute phase. Data are presented as median and interquartile range (IRQ). *p < 0.05 NS vs. S using Mann-Whitney U-test.

**Fig. 5** Logistic regression. MBL concentration in the acute phase < 1300* vs. ≥ 1300 ng/mL and the risk of in-hospital death. All patients are displayed in the upper part of the panel, men in the middle part of the panel and women in the lower part of the panel. First as univariate analysis and then APACHE II and SOFA scores are introduced separately. Data are presented as odds ratio (OR) and 95% confidence intervals. * denotes the indicator contrast with OR 1.00.
A second notable finding relates to changes in MBL levels in response to acute sepsis. Contrary to the expected, MBL levels decreased from baseline to the acute phase, especially in survivors, with a differential pattern in men and women.

The notion of MBL as an acute phase reactant stem from earlier findings. The promoter sequence of the MLB2 gene contains several consensus elements. As in other acute phase reactants, the transcription is enhanced by IL-6, dexamethasone and heat shock protein but inhibited by IL-1 [41, 42]. However, MBLs function as an acute phase reactant has been questioned since there is considerable heterogeneity in the acute response in different settings and the influence of genetic polymorphism is substantial. A slower and less obvious MBL response to infection or surgical trauma compared with other acute phase reactants, as C-reactive protein, and variable responses in sepsis have been reported [43–46].

In an Australian study, 41% of patients with pneumonia and blood stream infection had stable MBL levels through their hospital stay [44]. Further, they found that patients who were MBL deficient at study entry, failed to demonstrate a positive acute phase response into the normal range. This diverge from our results were 35% of patients with baseline values less than 500 ng/mL increased to 1500 ng/mL or more in the acute phase. Differences in patient selection and timing of blood sampling may account for these discrepancies.

Another main finding was that low pre-sepsis MBL levels were not identified as a risk for severe sepsis, septic shock or unfavourable outcome. This is contrary to some interpretations that low MBL levels or a state of MBL deficiency is associated with increased risk for infection and development of SIRS, sepsis, septic shock, and even sepsis related death [28, 30, 47]. Also, in this respect there are conflicting data. In a large population based study were 9245 individuals were genotyped and followed 8 to 24 years, no evidence for significant differences in infectious disease or mortality in MBL deficient individuals versus controls was found [32]. A study on intensive care patients could not find any difference in frequency of MBL2-polymorphism between patients and controls at baseline, and between patients classified as having sepsis or not [34].

Considering the biological function of MBL as a pathogen recognizing molecule that either directly or mediated via the associated serinproteases MAPS2 activate the complement pathway and enhance phagocytosis, it would not be surprising if a ready access of functional MBL are beneficial in case of an infection. However, if this leads to an exaggerated complement activation it could result in extensive tissue damage, detrimental for the host. Of note in our cohort of patients, none of the women with the highest MBL values at baseline died in hospital, while an increase or high levels in the acute phase did not prove to be beneficial, at least not for women. In theory, this could imply that an abundance of MBL allowing a rapid pathogen recognition and early neutralization prevents further, uncontrolled activation of other cascade systems with subsequent excessive inflammatory response and organ dysfunction. A delayed response with an increase of MBL when other components of the innate immune system already are set into action may impose additional, non-beneficial inflammatory responses. Partly supporting this notion are data indicating beneficial effects of low MBL levels in different settings [18–21, 23, 48–50]. Thus, MBL may have different effects in different situations and in different phases of acute illness. An alternative explanation for the finding that patients who died had higher MBL levels than survivors could relate to dysfunctional MBL with reduced ligand binding and opsonin function which could lead to reduced phagocytosis and reduced clearance from the circulation and higher free MBL levels. However, the assay used in this study is considered to predominantly detect oligomeric or “functional” MBL.

![Fig. 6 Univariate logistic regression. The difference in MBL levels between the acute phase and baseline (MBL_acute phase - MBL_baseline) and the risk of in-hospital death. All patients are displayed in the upper part of the panel, men in the middle part of the panel and women in the lower part of the panel. Data are presented as odds ratio (OR) and 95% confidence intervals. * denotes the indicator contrast with OR 1.00]
Most studies have not considered the possibility of sex-related differences and data are not presented stratified for sex. The value of MBL as a prognostic marker for outcome or patient selection for substitution or inhibitory therapy requires a deeper understanding of its action before implementation into clinical practice.

We were not able to find any association between MBL levels and degree of severity of acute sepsis, source of infection, infecting microorganism or other comorbidities. This was unexpected, since acute illness and co-morbidities might be expected to be accompanied by some degree of inflammation, also with corresponding MBL expression. A finding also unexpected in the light of reports that MBL deficiency is associated with recurrent respiratory infections and infections with gram-positive bacteria [16, 51–53]. However, the power to detect more subtle associations may have been restricted by the size of the study cohort.

Our results contradict findings from others that the presence of MBL variant alleles, and low MBL levels, associates with the development of sepsis, severe sepsis, and septic shock [28, 30]. There are also others who have not been able to show such distinct associations between severity of illness and MBL levels or genotype [26, 34, 44].

Limitations in the study design
In this study, only circulating plasma levels of MBL were determined, which ideally should have been combined with genotypes and studies of MBL function. More than 80 polymorphic sites are known, not all of known clinical relevance and only seven haplotypes are commonly found and studied were three different structural variants, B, C and D and the promoter haplotypes HY, LY and LX have a dominant effect on circulating MBL levels [10, 25, 33]. However, an individual’s MBL levels cannot be determined from its genetic variant alone, since there are considerable inter-individual variations and other yet unknown factors probably influence circulating levels [12, 13, 25, 33]. Still, a future study of sex-related MBL responses would ideally include genotyping. Further, due to lack of resources we were not able to specifically analyze MBL function, as with analysis of C4b deposit or MBL associated serine protease 2 (MASP-2).

The sample size was determined by access to pre-illness biomaterial, which affected the patient selection and limited the number of observations. For this reason, there is a majority of women of slightly younger age than the men. Patients do not entirely represent all patients consecutively admitted to the ICU, though their characteristics are representative for patients with sepsis at our ICU and we believe that there were sufficient observations to draw major conclusion from this explorative study.

The findings are empirical which can generate new hypothesis, and the study was not designed to assess possible pathophysiological mechanisms. Furthermore, the reported sex-related differences are similar to those previously reported for the adipokine leptin [35].

Summary and conclusions
In summary, we observed sex-related differences in MBL levels and kinetics related to sepsis survival. High levels or an increase of MBL in the acute phase of sepsis were associated with unfavourable outcome in women. We conclude that further evaluation of MBL response in acute sepsis should include a differentiated analysis with regard to gender. Further aspects of MBL response in sepsis needs to be elucidated before substitution with recombinant MBL or inhibitory therapy is considered in the future.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12950-020-00257-1.
Acknowledgements
The County Council of Västerbotten, Umeå University, the Swedish Medical Society, Swedish Heart and Lung Foundation, Capio, and the Kempe Foundation supported this study. The authors wish to express their gratitude to the Västerbotten Intervention Study (VIPS), the Northern Sweden MONICA project, the Mammary Screening Project, the Maternity Cohort of Northern Sweden, and the Medical Biobank and the funds that support these groups. We thank Åsa Ågren, Hubert Sjödin, Lennart Styrke and Eva Liedgren for expert technical assistance.

Authors’ contributions
SS and PL designed the study. SJ extracted and evaluated patient data and performed statistical analyses. GI contributed with statistical analysis including presentation of data in tables and figures. MA performed chemical analyses. SJ, SS and OW drafted the manuscript, and all authors revised the manuscript critically for important intellectual content. All authors approved the final version and are accountable for all aspects of the manuscript.

Funding
Funding that enabled collection, analysis, interpretation of data and writing the manuscript was received from the County Council of Västerbotten, Umeå University, the Swedish Medical Society, Capio, and the Kempe Foundation supported this study. SSÖ was supported by the Swedish Heart and Lung Foundation, and by the County Council of Västerbotten (ALF). Open access funding Umea University.

Availability of data and materials
All results and data are kept in the section of Anesthesiology and Intensive Care Medicine, Department of Surgical and Perioperative Science; Umeå University. These will be made available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the Regional Ethical Review Board in Care Medicine, Department of Surgical and Perioperative Science; Umeå University. Consent for publication of data and blood samples at the moment of the baseline survey. Consent for publication
Data was de-identified, after collection, and therefore there was no consent required from individual patients, according to the ethical approval.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Surgical and Perioperative Sciences, Anesthesiology and Intensive Care Medicine, Umeå University, SE-901 87 Umeå, Sweden.
2Department of Public Health and Clinical Medicine, Medicine, Umeå University, SE-901 87 Umeå, Sweden.

Received: 15 May 2019 Accepted: 31 July 2020
Published online: 12 August 2020

References
1. Sandquist M, Wong HR. Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment. Expert Rev Clin Immunol. 2014; 10:1349–56.
2. Honore PM, Jacobs R, De Waele E, Spapen HD. Biomarkers to detect sepsis: a "burning" issue but still a long way to go*. Crit Care Med. 2014;42:2137–8.
3. Singh SS, Cheung RC, Wong JH, Ng TB. Mannose binding lectin: a potential biomarker for many human diseases. Curr Med Chem. 2016;23:3847–60.
4. Radnay ZB, Udvardy M, Papp M, Harfalvi J, Rejto L, Imai I, Illes A, Kiss A. Evaluation of mannose-binding Lectin is a useful approach to predict the risk of infectious complications following autologous hematopoietic stem cell transplantation. Transplant Proc. 2016;48:3397–405.
5. Jensenius JC, Jensen PH, McGuire K, Larsen JL, Thiel S. Recombinant mannose-binding lectin (MBL) for therapy. Biochem Soc Trans. 2003;31:763–7.
6. Sugih T, Fujiwara T, Kojima C. Latest approaches for efficient protein production in drug discovery. Expert Opin Drug Discovery. 2014;9:1189–204.
7. Keizer MP, Wouters D, Schlabach LJ, Kuipers TW. Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy. Mol Immunol. 2014;61:174–84.
8. Malhotra R, Lu J, Holmiskov U, Sim RB. Collectins, collectin receptors and the lectin pathway of complement activation. Clin Exp Immunol. 1994;97(Suppl 2):4–9.
9. Liposome RI, Suniya M, Hill AV, Lau YL, Levinsky RJ, Summerfield JA, Turner MW. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992;1:709–15.
10. Madsen HO, Garred P, Thiel S, Kurzhalas JA, Lammi LU, Ryder LP, Sjøgaard A. Interplay between promoter and structural gene variants control basal serum level of mannann-binding protein. J Immunol. 1996;155:3013–20.
11. Madsen HO, Satz ML, Hogh B, Sjøgaard A, Garred P. Different molecular events result in low protein levels of mannann-binding lectin in populations from Southeast Africa and South America. J Immunol. 1998;161:3169–75.
12. Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency—revisited. Mol Immunol. 2003;40:73–84.
13. Best LG, Ferrell RE, Decroo S, North KE, Maccluer JW, Zhang Y, Lee ET, Howard BD, Umanns J, Palmieri V, Garred P. Genetic and other factors determining mannose-binding lectin levels in American Indians: the strong heart study. BMC Med Genet. 2009;10:5.
14. Ozkan H, Koksal N, Cetinkaya M, Kılıç S, Celebi Ş, Oral B, Budak F. Serum mannose-binding lectin (MBL) gene polymorphism and low MBL levels are associated with neonatal sepsis and pneumonia. J Perinatol. 2012;32:310–7.
15. Holdaway J, Deacock S, Williams P, Karim Y. Mannose-binding lectin deficiency and predisposition to recurrent infection in adults. J Clin Pathol. 2016;69:731–6.
16. Roy S, Knox K, Segal S, Griffiths D, Moore CE, Welsh KI, Smarason A, Day NP, McPheat WL, Crook DW, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet. 2002;359:1569–73.
17. Eisen DP, Dean MM, Boermeester MA, Fidler KJ, Gordon AC, Kronborg G, Kun JF, Lau YL, Payeras A, Valdmarsen H, et al. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis. 2008;47:510–6.
18. Muller S, Schaffer T, Floegner B, Seibold-Schmidt B, Schneider J, Takahashi K, Darfeuille-Michaud A, Vazeille E, Schoepfer AM, Seibold F. Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens. Gut. 2010;59:1493–500.
19. Monsey L, Best LG, Zhu J, DeCroo S, Anderson MZ. The association of mannose-binding lectin genotype and immune response to chlamydia pneumoniae: the strong heart study. PLoS One. 2019;14:e0210640.
20. Ruseva M, Kolev M, Dagnares-Hansen F, Hansen SB, Takahashi K, Ezekowitz A, Thiel S, Jensenius JC, Gadgeva M. Mannann-binding lectin deficiency modulates the humoral immune response dependent on the genetic environment. Immunology. 2009;127:279–88.
21. Takahashi K, Kurokawa K, Moyo P, Jung DJ, Chigweshe L, Paul E, Lee BL. Intraluminal immunization with wall teichoic acid (WTA) elicits and augments an anti-WTA IgG response that protects mice from methicillin-resistant Staphylococcus aureus infection independent of mannane-binding lectin status. PLoS One. 2013;8:e67939.
22. Zhao L, Ohtaki Y, Yamaguchi K, Matsushita M, Fujita T, Yokochi T, Takada H, Endo Y. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood. 2002;100:3233–9.
23. Guttormsen HK, Stuart LM, Shi L, Canoll MC, Chen J, Kasper DL, Ezekowitz RA. Takahashi K. Deficiency of mannose-binding lectin greatly increases antibody response in a mouse model of vaccination. Clin Immunol. 2009;130:264–71.
24. Garred P, Thiel S, Madsen HO, Ryder LP, Jensenius JC, Sjøgaard A. Gene frequency and partial protein characterization of an allelic variant of mannann binding protein associated with low serum concentrations. Clin Exp Immunol. 1992;90:717–21.
25. Steffensen R, Thiel S, Varming K, Jersild C, Jensenius JC. Detection of structural gene mutations and promoter polymorphisms in the mannann-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J Immunol Methods. 2000;241:33–42.
26. Eisen DP, Dean MM, Thomas P, Marshall P, Gerns N, Healey S, Quinn J, Mchintosh RM, Lipman J. Low mannann-binding lectin function is
